Brooke Gambino, NP
Acute Care · Phoenix, AZNPI 1619631587
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), other and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Angiodynamics, Inc. at 33.9% of the total. Reporting peaked in 2022 at $7,183 and has fallen 92.9% since, to $507 in 2025. Among acute care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $76.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Medtronic$2K
- Cvrx, Inc.$2K
- Amgen$797
- Abiomed$448
- Edwards Lifesciences$428
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1,80217%
- Food & beverage$5,15349%
- Education$500%
- Other$3,60034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $3,600 |
| Medtronic | 34 | $2,129 |
| Cvrx, Inc. | 9 | $1,527 |
| Amgen | 29 | $797 |
| Abiomed | 8 | $448 |
| Edwards Lifesciences | 3 | $428 |
| Boston Scientific | 5 | $303 |
| Penumbra, Inc. | 2 | $282 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $262 |
| Novo Nordisk | 7 | $127 |
| Johnson & Johnson | 6 | $108 |
| Novartis | 4 | $91 |
| Inspire Medical Systems, Inc. | 1 | $88 |
| Merck | 5 | $87 |
| Lilly USA, LLC | 1 | $77 |
| Esperion Therapeutics, Inc. | 1 | $75 |
| Impulse Dynamics (USA) Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $25 |
| Acera Surgical, Inc. | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Veryan Medical Incorporated | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Atherectomy Catheter 1.5 mm OTW$3,600
- Auryon Atherectomy Catheter 2.0 mm OTW$3,600
- Auryon Atherectomy Catheter 0.9 mm OTW$3,600
- Barostim Neo System$1,144
- VenaSeal$1,009
- Indigo System$282
- LINQ II$272
- PASCAL$252
- Repatha$222
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$144
- Varithena Administration Pack$130
- TurboHawk$128
- LifeVest$127
- Impella$123
How this compares
$10,605 in reported general payments places this provider in the 95th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 27 | $18,050 |
| EliquisApixaban | 20 | $13,258 |
| FarxigaDapagliflozin Propanediol | 17 | $10,543 |
| Repatha SureclickEvolocumab | 13 | $8,134 |
| Rosuvastatin Calcium | 18 | $346 |
| Atorvastatin Calcium | 45 | $317 |
| SotalolSotalol Hcl | 16 | $275 |
| Hydralazine Hcl | 13 | $215 |
| Metoprolol Succinate | 30 | $189 |
| ClopidogrelClopidogrel Bisulfate | 35 | $173 |
| Potassium Chloride | 20 | $105 |
| Amlodipine Besylate | 15 | $90 |
| Furosemide | 28 | $74 |
| Lisinopril | 15 | $66 |
| Losartan Potassium | 19 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $91 | $18,05027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 acute care providers in Arizona.
Other acute care in Phoenix
- Kim KrmpoticPhoenix$79K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
- Nicole RauscherPhoenix$12K
- Kelly WesselhoffPhoenix$9K
- Jenna GonzalesPhoenix$8K
- Kristen HudsonPhoenix$8K
- Tammy TyreePhoenix$8K
- Lydia ChongPhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.